The explosive growth of GLP-1 receptor agonists like semaglutide and tirzepatide creates new considerations for the millions of adults who may eventually require joint replacement, spinal fusion, or fracture repair. As these medications become standard care for diabetes and weight management, understanding their bone-related effects becomes critical for surgical planning and recovery optimization.
This comprehensive review from Hospital for Special Surgery reveals a complex picture regarding bone health impacts. Laboratory studies indicate GLP-1 agonists may actually strengthen bones by enhancing mineral density and reducing bone breakdown through multiple cellular pathways. However, clinical evidence presents conflicting results on fracture risk reduction, suggesting the relationship between these medications and bone strength remains poorly understood in real-world populations.
The surgical implications extend beyond bone effects. GLP-1 agonists significantly slow gastric emptying, creating anesthesia complications and potential drug interactions during procedures. Yet for diabetic and obese patients facing orthopedic surgery, the metabolic benefits—improved glucose control and preoperative weight reduction—may outweigh these concerns. The review particularly emphasizes spine surgery considerations, where both bone quality and metabolic health critically influence outcomes.
This analysis highlights a significant knowledge gap as GLP-1 use continues expanding. The disconnect between promising laboratory findings and inconsistent clinical bone health data suggests current evidence inadequately guides perioperative management. Given that orthopedic procedures often target older adults with diabetes—prime candidates for GLP-1 therapy—resolving these uncertainties represents an urgent clinical priority requiring dedicated bone health studies in surgical populations.